Merck breaks below $139.50 after nemtabrutinib trial ends
Merck fell below $139.50 after ending its Phase 3 nemtabrutinib trial. FxPro sees $129.00 as the next support and says a daily close above $139.50 would cancel its bearish scenario.
By Daniel Okafor
3 min read

What's News
- Merck & Co., Inc. broke below $139.50 and fell for a second day.
- The $139.50-$151.50 sideways range held from the end of August.
- FxPro’s next support target is $129.00, previously resistance in early July.
- Merck ended its Phase 3 nemtabrutinib trial on an independent monitoring committee’s advice.
- A daily close above $139.50 would cancel the bearish scenario.
By Daniel Okafor
Merck & Co., Inc. broke below $139.50, according to FxPro’s TradingView analysis, which points to $129.00 support. The chart reports a second day of losses after Merck ended its Phase 3 trial of the blood-cancer drug nemtabrutinib on the advice of an independent monitoring committee. TradingView identifies the chart as BATS:MRK and links it to NYSE symbol MRK.
What changed in Merck’s trading range?
FxPro treats $139.50 as the lower boundary of a sideways range capped at $151.50. The range held from the end of August.
Buyers defended $139.50 twice: at the start of October, during wave A, and at the end of October, during wave i. Sellers answered at $151.50 on every rally, including wave ii at the start of November.
The break also pushed the shares below their daily rising trendline from June. FxPro therefore sees two technical failures: the range floor gave way, and the June uptrendline broke.
How does FxPro read the wave structure?
In FxPro’s analysis, the breakdown accelerated the active impulse wave iii of the C wave. Both sit inside the ABC correction labeled (2), which began at the end of August. The setup does not describe an isolated dip. It identifies the current decline as part of a larger correction, with wave iii still active.
“Given the strong bearish momentum, Merck can be expected to fall further toward the next support level 129.00 (target price for the completion of the active wave iii), which acted as resistance at the start of July,” FxPro said.
Why does $129.00 matter?
$129.00 is the next support objective and the stated completion target for wave iii. The chart also records $129.00 as resistance at the start of July. FxPro’s bearish path assumes the breakdown holds and selling continues toward that former resistance, now treated as support.
Two thresholds now govern the forecast. $129.00 is the prospective support and downside target. $139.50 is the level needed to invalidate the setup and the potential destination of a corrective rebound from $129.00.
What would invalidate the call?
FxPro’s next scenario is conditional on $129.00 holding. If it does, the chart expects a corrective advance toward $139.50, which has become resistance. A daily close above $139.50 would cancel the bearish scenario. Below $139.50, the analysis assigns control to sellers rather than buyers.
The first checkpoint is therefore $129.00, not $139.50. It must arrive as support for the projected rebound. The second checkpoint is $139.50. A close above it reverses the current roles, turning the former range floor into another resistance marker.
How did the trial affect the session?
The Phase 3 trial ending was the immediate company news attached to the second-day decline. Merck ended the study on the advice of an independent monitoring committee.
The source does not state why the committee advised termination, and the chart provides no efficacy or safety detail. The technical call therefore rests on the price break, while the trial decision supplies the news backdrop.
What broader pressure does FxPro cite?
“Sellers stay in control below 139.50, with drug-pricing pressure on large-cap pharma adding to the headwinds,” FxPro said. The chart places Merck’s stock-specific breakdown inside a broader large-cap pharmaceutical problem. It offers no pricing figures and names no pricing measure, so the sector claim remains a qualitative headwind in the analysis.
Price will now test FxPro’s two thresholds. A hold at $129.00 could support a corrective rally toward $139.50. A daily close above $139.50 would void the bearish setup. Until one of those thresholds resolves, the trial decision and drug-pricing pressure reinforce the near-term selling case.
Source: tradingview.com
More from Daniel Okafor
Show full bio
Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.
2,417 articles